NIST Spectroscopic Measurement Standards
The National Institute of Standards and Technology (NIST) has developed Standard Reference Material (SRM) 2082 as a pathlength standard for UV absorbance measurements for use with the new generation of microvolume spectrophotometers and short-pathlength cuvettes.
science photo/shutterstock.com
Abstract
Ultraviolet (UV) absorbance measurements provide a rapid and reliable method to determine protein concentrations. The National Institute of Standards and Technology (NIST) has developed Standard Reference Material (SRM) 2082as a pathlength standard for UV absorbance measurements for use with the new generation of microvolume spectrophotometers and short-pathlength cuvettes. Short pathlengths are used with high-concentration targets to ensure that absorbance values are within the optimal range. The short-pathlength instruments and cuvettes also reduce the required volumes to conserve valuable samples. The authors compared the results obtained with high-quality dual-beam spectrophotometers and short-pathlength cuvettes to the results obtained from a microvolume spectrophotometer and a microvolume plate reader. SRM 2082 can be used to accurately calculate pathlength values, thereby increasing the accuracy in subsequent measurements using the short-pathlength cuvettes and microvolume absorbance instruments. RM 8671 (reference material, the NISTmAb) can then be used to ensure the accuracy and reproducibility of protein concentration measurements by providing an industrially relevant reference material, a well-characterized monoclonal antibody.
Click here to view a PDF of this article.
Peer-Reviewed
Submitted: Jan. 22, 2018
Accepted: Feb. 16, 2018
About the Authors
Kenneth D. Cole*is group leader bioassay methods, Kenneth.cole@nist.gov; Paul DeRose, Brian Lang, John Schiel, and Aaron Urbas are research chemists; Hua-Jun He and Erica V. Stein are research biologists; Evelyn Solis is summer student; and Steve Choquette is director, Office of Reference Materials-all are at NIST.
*To whom all correspondence should be addressed.
Article Details
BioPharm International
Vol. 31, Number 4
April 2018
Page: 22–34
Citation
When referring to this article, please cite as K.D. Cole et. al, “NIST Spectroscopic Measurement Standards,” BioPharm International 31 (4) 2018.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
